Solomon Moshkevich Sells 1,204 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,204 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $254.07, for a total transaction of $305,900.28. Following the sale, the insider directly owned 132,429 shares of the company’s stock, valued at approximately $33,646,236.03. This represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $260.49, for a total transaction of $263,094.90.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $272.90, for a total transaction of $818,700.00.
• On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $218.43, for a total transaction of $655,290.00.
• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The stock was sold at an average price of $202.84, for a total value of $335,091.68.
• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The stock was sold at an average price of $203.69, for a total value of $693,564.45.

Natera Stock Performance

Shares of Natera stock opened at $269.66 on Friday. Natera, Inc. has a one year low of $131.81 and a one year high of $288.04. The stock’s fifty day moving average is $245.48 and its 200 day moving average is $221.90. The stock has a market cap of $38.62 billion, a P/E ratio of -165.44 and a beta of 1.51.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Analyst sentiment remains favorable: Canaccord Genuity raised its price target to $330 and maintained a “buy” rating, while the broader analyst consensus is “Moderate Buy” with an average target of $267.83. Analyst and Natera market coverage
• Positive Sentiment: Institutional ownership and recent buying provide additional support. Major investors including Coatue Management, Wellington Management, Norges Bank, JPMorgan and AQR Capital Management increased their positions; institutions collectively own approximately 99.9% of the stock.
• Neutral Sentiment: CFO Michael Burkes Brophy sold 5,064 shares worth about $1.28 million, while CEO Steven Leonard Chapman sold 5,770 shares for roughly $1.48 million. Because the sales were pre-arranged and intended to satisfy tax-withholding obligations, they are less likely to signal reduced management confidence. CFO SEC filing CEO SEC filing
• Neutral Sentiment: Insiders John Fesko and Solomon Moshkevich also sold shares under similar tax-related plans, while retaining sizable positions. Fesko’s latest sale involved 782 shares worth approximately $203,700. Fesko SEC filing
• Negative Sentiment: The concentration of insider selling could create modest short-term selling pressure and may prompt valuation concerns. Natera also trades at a high valuation relative to its earnings profile, with a negative trailing price-to-earnings ratio, although no new operational warning accompanied the filings.

Institutional Investors Weigh In On Natera

A number of institutional investors and hedge funds have recently bought and sold shares of NTRA. Integrated Wealth Concepts LLC boosted its stake in shares of Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after acquiring an additional 96 shares during the period. NewEdge Advisors LLC grew its position in shares of Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after purchasing an additional 1,847 shares in the last quarter. Focus Partners Wealth raised its stake in Natera by 8.6% during the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after purchasing an additional 474 shares during the period. Sivia Capital Partners LLC bought a new stake in Natera during the 2nd quarter valued at approximately $298,000. Finally, WINTON GROUP Ltd bought a new stake in Natera during the 2nd quarter valued at approximately $558,000. 99.90% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

NTRA has been the topic of several recent research reports. Robert W. Baird set a $265.00 price objective on Natera in a research note on Friday, May 8th. Evercore reiterated an “outperform” rating and set a $300.00 price objective on shares of Natera in a research note on Monday, July 6th. Canaccord Genuity Group increased their target price on shares of Natera from $285.00 to $330.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Barclays decreased their target price on shares of Natera from $280.00 to $260.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $267.83.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.